Streetwise Reports' Article Archives — Current Month (15)
Washington D.C. Pharma Co. Receives FDA Acceptance (01/28/2025)
Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) recently received FDA acceptance of its request for a hearing regarding its tradipitant New Drug Application, reported an H.C. Wainwright & Co. analyst.
Biotech's Target Price 183.757% Higher Than Current (01/24/2025)
Read on to see why D. Boral Capital analyst Jason Kolbert gave IMUNON Inc. (IMNM:NASDAQ) a high target price.
AI Infrastructure Push: US$500 Billion Investment Accelerates Drug Discovery (01/23/2025)
Rakovina Therapeutics Inc. (RKV:TSX.V) highlights the transformative potential of the US$500 billion Stargate Initiative, set to revolutionize AI-driven drug discovery. Learn how this landmark investment could redefine oncology breakthroughs.
Biopharma Shares Multiple 2025 Catalysts (01/17/2025)
Innate Pharma SA's (IPHA:NASDAQ; IPH:Paris) long-term corporate strategy led to it recieving a Buy rating from H.C. Wainwright & Co.
Advanced AI Solutions Deliver Hope for CNS Cancer Treatment (01/15/2025)
Rakovina Therapeutics Inc. (RKV:TSX.V) has identified AI-designed drug candidates targeting advanced cancer treatments with CNS penetration. Read more about how this breakthrough could redefine oncology innovation.
Tech Innovator Achieves Breakthrough Multi-Market Success (01/15/2025)
Clean technology company BioLargo Inc. (BLGO:OTCQX) announces it had a "widely successful" and "transformative" 2024 and is looking forward to more revenue growth in 2025. Read why one expert thinks investors should be doubling down on the stock.
AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections (01/10/2025)
Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research.
Biotech Advances Breakthrough Cancer Treatment Results (01/10/2025)
Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note.
Pharma Innovator Reveals Groundbreaking Diabetes Treatment (01/10/2025)
Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share.
Should You Double Down on This Story Stock? (01/07/2025)
Chris Temple of The National Investor explains why he believes you might want to double down on BioLargo Inc. (BLGO:OTCQX).
AI Company Unlocks Breakthrough Medical Diagnostics Platform (01/06/2025)
One company being listed on Cboe Canada starting January 8 is using AI and smartphones to help patients get quick and accurate diagnosis of their sore throats, helping to battle microbial resistance that threatens the effectiveness of antibiotics worldwide.
Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech (01/06/2025)
CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence.
Pharma Innovator Unlocks Multi-Disease Treatment Potential (01/03/2025)
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating.
Drug Innovator Launches Pivotal Cancer Trial Breakthrough (01/03/2025)
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note.
Miami Biopharma Sells Part of Business and Begins New Clinical Trial (01/02/2025)
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating.
More Archives
2025
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
